DBV Technologies S.A. (DBVT)
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults.
Beschreibung
Börse
Branche
Land
Aktiv:keine
| Unternehmen | Rating | |||||
|---|---|---|---|---|---|---|
| Daten werden geladen… | ||||||
Gespeicherte Screens und vollständige Daten: mit dem Abo
Abonniere, um Filter zu speichern und alle Spalten und Ratings freizuschalten.
Abonnieren - 24,90 €/Monat